Observational studyBMC ophthalmology2026
Predictive value of peripheral blood lymphocytes for glaucoma susceptibility: a clinical observational study.
Observational study in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeripheral blood lymphocytes constitute a central arm of the immune system, and their role in the initiation and progression of glaucoma is attracting increasing attention.
objectiveTo investigate whether shifts in peripheral lymphocyte-subset profiles are associated with primary open-angle glaucoma susceptibility and to evaluate the predictive value of lymphocyte-related indices for glaucoma onset.
methodsThis retrospective case-control study enrolled 428 consecutive primary open-angle glaucoma patients attending the Department of Ophthalmology between January 2023 and January 2024 (glaucoma group), and 475 age- and sex-matched healthy subjects undergoing routine health screening during the same period (HC group). Demographic data, laboratory results, and quantified peripheral lymphocyte subsets were extracted from electronic medical records. Logistic regression was used to identify glaucoma-related lymphocyte variables, and evaluated their discriminative performance using ROC curves, calculating the AUC, optimal cut-off, sensitivity, and specificity.
resultsCompared with controls, glaucoma patients exhibited significantly higher absolute counts and percentages of CD4⁺ T cells, lower absolute counts and percentages of CD8⁺ T cells and NK cells, and an elevated CD4⁺/CD8⁺ ratio (all P < 0.05). After multivariable adjustment, an increased CD4⁺/CD8⁺ ratio (OR = 8.427, 95% CI 2.823–25.161, P < 0.001) and reduced NK-cell count (OR = 0.727, 95% CI 0.666–0.794, P < 0.001) emerged as factors independently associated with glaucoma. ROC analysis yielded an AUC of 0.749 (95% CI 0.719–0.777, P < 0.001) for the CD4⁺/CD8⁺ ratio (optimal cut-off > 1.57; sensitivity 57.94%, specificity 82.32%) and 0.657 (95% CI 0.625–0.688, P < 0.001) for NK-cell count (cut-off ≤ 525 cells/µL; sensitivity 79.67%, specificity 47.58%). Combining the two indices increased the AUC to 0.787 (95% CI 0.759–0.813, P < 0.001), with sensitivity 67.76% and specificity 75.16%. The AUC of the combined model was significantly superior to that of either index alone (all P < 0.001).
conclusionsIn this retrospective analysis, peripheral CD4⁺ and CD8⁺ T-cell imbalances were associated with glaucoma susceptibility and demonstrated moderate predictive accuracy for disease onset. The CD4⁺/CD8⁺ ratio, especially when combined with NK-cell count, shows promise as a potential candidate biomarker for early glaucoma risk assessment, pending prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.